Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Tolerability of Initiating Aripiprazole Lauroxil in Subjects With Schizophrenia Who Are Inadequately Treated With Paliperidone Palmitate or Risperidone Long Acting Injection

NCT02634320 is registered in ClinicalTrials.gov with Alkermes, Inc. as lead sponsor.

NCT NCT02634320
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02634320 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Tolerability of Initiating Aripiprazole Lauroxil in Subjects With Schizophrenia Who Are Inadequately Treated With Paliperidone Palmitate or Risperidone Long Acting Injection
Lead sponsor
Alkermes, Inc.
Phase
Phase 4
Overall status
Completed
Start date
December 31, 2015
Completion date
July 11, 2017
Enrollment
51 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia